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This knowledge-based activity is targeted for all pharmacists
and is acceptable for 1.0 hour (0.1 CEU) of continuing
education credit. This course requires completion
of the program evaluation and at least a 70 percent grade
on the program assessment questions.

ACPE Universal Activity Number(UAN): 0048-0000-14-216-HOl-P
Objectives
After completion of this program, the reader should be able
to:
1. Identify the different types of diabetes and each of
their pathophysiologies.
2. Name several investigational methods for insulin
administration.
3. Describe the pharmacokinetics and pharmacodynamics ofTechnosphere® insulin.
4. Explain the advantages and disadvantages of inhaled
insulin compared to injectable insulin.
5. Evaluate the efficacy and safety of Technosphere®
insulin based on data from clinical trials.
Abstract
Diabetes is an endocrine disease caused by deficiency or malfunction of insulin that results in high blood glucose levels
and places patients at higher risk for a number of complications. This chronic disease is difficult to manage and affects
millions of people in the United States, costing the health
care system billions of dollars a year. Of a variety of antidiabetic agents used to control blood glucose, insulin is perhaps
the most effective, but until recently it was only available in
injectable form. As of June 27, 2014, a new inhaled insulin
called Afrezza® (Technosphere® insulin) was approved
by the U.S. Food and Drug Administration (FDA) and will
soon be coming to market This rapid-acting insulin is administered through the lungs and offers an alternative to traditional dosage forms. This article further explores some
background about Technosphere® insulin, its mechanism of
action and literature regarding its efficacy.
Key Terms
Administration, Inhalation; Blood Glucose; Chronic Disease;
Diabetes Mellitus; Disease Management; Endocrine System
Diseases; Humans; Hyperglycemia; Hypoglycemic Agents;
Insulin; Insulin, short-acting; Review Literature
Introduction
According to the 2014 National Diabetes Statistics Report,
approximately 29.1 million people (9.3%) in the United
States have diabetes.1 Direct and indirect health care costs
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related to diabetes are estimated to total about $245 billion a
year, placing a large burden on patients and providers alike.
Disease State
Diabetes mellitus (DM) is an endocrine disease that results in
high blood glucose levels due to deficiency or malfunction of
the hormone, insulin, that is responsible for most of glucose
absorption from the blood stream.1 Patients with diabetes
are at higher risk than nondiabetics for a number of other
health complications including hypoglycemia or hyperglycemia, hypertension, cardiovascular problems, blindness and
kidney disease. Diabetes is usually classified into type I, type
II and gestational diabetes (GDM). Type I DM (approximately
5% of diabetes cases) is caused by the body's immune
system destroying the insulin-producing beta cells in the
pancreas, resulting in an insulin deficiency without cure or
prevention. Type I DM usually appears in young adults,
although it can happen at any age. Patients diagnosed with
type I DM require exogenous insulin to survive. Type II DM
(90 to 95% of diabetes cases) starts with insulin resistance in
various tissues, placing an increased demand for insulin on
the beta cells of the pancreas. The increased stress on these
cells eventually reduces their ability to produce enough insulin to meet the demand. Treatment for type II DM depends on
the patient's individual combination of insulin resistance and
reduced insulin secretion. Gestational diabetes develops during pregnancy when increased blood glucose levels cause the
mother to develop intolerance to glucose. During pregnancy,
high blood glucose is dangerous for the mother and fetus and
requires treatment Even after birth, both mother and child
are at increased risk for type II DM.
Treatment
Type I DM requires insulin therapy to maintain normal blood
glucose levels.1 Type II DM has a wider variety of progressive
treatment options including oral agents (such as metformin, glucagon-like peptide-1 agonists and others) and insulin.2 These
agents can be used in conjunction to maintain glycemic control.
Although insulin replacement therapy is acknowledged as
the most effective glucose-reducing treatment, its administration by injection is a considerable barrier to many patients.3 A study performed by Cramer and Pugh estimated
that subjects taking insulin used 77 percent of their prescription on average.4 Although this average indicates an intention to take the insulin as prescribed, there was still an
underuse of insulin and this often resulted in poor glycemic
control. Peyrot and colleagues suggested that reasons for
nonadherence with insulin therapy were often related to
discomfort or inconvenience of the injection.3 Of 502 subjects
studied, 23 to 25 percent reported the injections interfered
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with various daily activities, 22 percent had to mentally prepare themselves before each injection and 33 percent experienced a level of dread toward taking their insulin injections.3
Due to these barriers for insulin administration, the pharmaceutical industry continues to search for alternative insulin
delivery methods. Potential alternatives such as oral, nasal or
transdermal insulin often have low bioavailability.s
Exubera® (insulin inhalation), produced by Pfizer, was approved by the FDA on Jan. 27, 2006, and became the first inhaled insulin to make it to market 6 Insulin inhalation was
shown to be as effective as short-acting injectable insulin,
although it had to be administered in conjunction with an
injectable long-acting basal insulin.7 Despite its efficacy,
Pfizer decided to withdraw insulin inhalation from the market in 2007 due to poor sales and low demand.a
Afrezza (Technosphere® insulin, abbreviated TI) is a new
inhaled insulin developed by MannKind Corporation and was
approved by the FDA for marketing as of June 27, 2014.9 It is
a very rapid-acting insulin dispensed as a powder from a
DreamBoat® inhaler (Figure 1). The DreamBoat® inhaler is
small, portable and easy to use, giving Tl an edge in convenience over previous inhaled insulin. Technosphere® insulin
does not replace long-acting basal insulin, but it could potentially reduce the number of injections that a patient has to
take. Clinical studies indicate promising efficacy results, but
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patients and prescribers may hesitate to use Tl due to the
negative impression left by the withdrawal of Exubera®
(insulin inhalation). The purpose of this article is to evaluate
the mechanism of action and clinical significance of Tl, supported by data from clinical trials, and to educate pharmacists about this new medication.
About Technosphere® Insulin
Technosphere® insulin is an inhaled, prandial, very rapidacting insulin product.10.11 The specially-formulated powder
is available for absorption via the lung and achieves 37 percent of the bioavailability of subcutaneous insulin administration. The formulation method involves the use of an
excipient, fumaryl diketopiperazine (FDKP), which selfassembles via hydrogen bonds in a slightly acidic environment The hydrogen bonding forms microspheres, which are
optimally sized for inhalation deep into the lung. The FDKP
microsphere formation can be used to incorporate peptides
and proteins (such as insulin) into a solution. The newly formed
microspheres containing the drug product are freeze-dried to
create the powder used in the inhalers for administration.
When a patient inhales this product, the microspheres are
introduced into the neutral pH of the lungs allowing for the
rapid and extensive absorption of insulin into systemic circulation. Once the insulin is absorbed via the lung mucosa into
systemic circulation, the insulin mechanism of action is the
same as with subcutaneous and intravenous administration

Figure 1: DreamBoat® inhaler marketed with Technosphere® insulin.
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Used with permission of Afrezza (insulin human) Inhalation powder [package insert on the Internet].
Danbury (CT): MannKind Corporation; 2014 Jun [cited 2014 Oct 9].
Available from: www.mannkindcorp.com/Collateral/Documents/English-US/ Afrezza_Prescribinglnformation.pdf.
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methods: acting as a hormone that helps the body utilize glucose by pulling glucose from the blood into the cells to use
for energy.
As a mealtime insulin, Tl reaches peak levels of insulin concentration within 15 minutes of administration, much quicker than current rapid-acting injected insulin products
(e.g., aspart, lispro, glulisine insulin reach peak levels between 30 and 90 minutes).10. 11. 12 This quick time-to-peak
also leads to higher maximum concentrations relative to injected insulin. Technosphere® insulin has faster elimination
from the body and, coupled with the fast onset of action, ithis
more closely resembles endogenous prandial insulin release
than currently available rapid-acting injected insulin.
Studies show that patients with chronic obstructive pulmonary disease (COPD) and those who smoke do not show evidence of decreased efficacy with the use of this product,
including mean peak insulin levels, median time to achieve
maximum concentrations and mean insulin exposure time
from zero to 240 minutes post-dose.10,11,11
Adverse effects with Tl include hypoglycemia and cough
(25% and 19%, respectively). 10,11,14 Other adverse effects
discovered were anemia and suspected hypersensitivity. Another concern with inhalation administration is that there
can be accumulation or deposition of the excipient FDKP and
insulin in the lungs. Evidence shows that both FDKP and insulin concentrations in the lung decline to minimal levels
(from 12% to 0.3%) over a 12-hour period after taking a
dose.10.11.1s.16

Comparison
A study by Rave and colleagues, which compared Tl versus
subcutaneously injected normal human insulin in postprandial coverage, indicated that peak blood glucose levels were
significantly lower with the use of TJ.1 4 Technosphere®
insulin also showed improved results with lower postprandial blood glucose (PPG) levels compared to that of regular
insulin 30 to 120 minutes following a meal. Several studies
show that Tl and biaspart insulin (biaspart insulin is a human insulin analogue suspension containing 70% insulin
aspart protamine suspension and 30% insulin aspart
[rDNA origin]) produced similar decreases of the patient's
glycosylated hemoglobin (HbAlc) (at one year, -0.58%
and -0.70%, respectively).10.11 However, Tl was shown to
impact fasting plasma glucose (FPG) levels more than biaspart insulin (one year average=171 versus 208mg/dL,
respectively, p=0.0001). l0.11.11.10
Patient Counseling/Education Points
One limitation seen in the past with inhaled insulin products
(such as Exubera®) was ensuring proper use of the special
inhaler, which was produced specifically for inhalation of
insulin.10.11 With the past product, the inhaler was larger and
difficult to use. The Exubera® inhaler also had to be cleaned
in a specific way and replaced frequently with a new inhaler.
Technosphere® insulin utilizes an improved inhaler, which
provides for easier use. The package insert for Tl provides
clear instructions for its use.9
4

Main points for patient counseling include: 9
• The cartridges must be refrigerated.
• The inhaler and the cartridge must be at room temperature for at least 10 minutes prior to its inhalation and administration.
• When the patient is using the inhaler, it must remain
level and upright in the proper orientation; this is because the cartridge is punctured when it is placed into
the base of the inhaler, and the powder becomes loose
and can spill out if not kept parallel to the ground.
• This inhaler must be thrown away and exchanged
for a new one every 15 days.
• Inside the packaging, there are two blister cards in a
foil pack.
In each blister card, there are five strips, and
each strip contains three cartridges.
A patient is to rip off one strip at a time when
using this product
When a strip is torn from the main blister card,
the strip (of three cartridges) must be used
within three days; after that it must be thrown
away.
• The blue cartridges contain four units of insulin, and
the green cartridges contain eight units of insulin.
Each dispensed package will only come in one
strength (blue [four units] or green [eight
units]).

Literature Review
Trial 1

Tack and colleagues performed a double-blind, placebocontrolled, randomized controlled trial as part of phase 2
clinical trials for the approval of Tl.19 The trial was designed
to test efficacy and evaluate dose-dependent response of four
different doses of Tl and compare them to placebo over the
course of 11 weeks. The population used included 227 patients with type II DM and poor glycemic control with other
medications. In addition to either Tl or placebo, all patients
were switched from their previous regimens to insulin
glargine for basal maintenance dosing. The subjects were
then randomized into five groups: Tl cartridge doses of 14,
28, 42 or 56 unit equivalents (U*) or placebo. Assuming administration by inhalation provides a bioavailability of 26
percent, the Tl doses were assigned equivalents to usual subcutaneous regular human insulin of3.6, 7.3, 10.9 and 14.6 U*,
respectively. Patients to be given the higher doses started an
initial dose of 3.6 U* and were titrated up by 3.6 U* per week
until the assigned dose was reached. Efficacy endpoints included reduction in HbAlc, area under the glucose curve
(AUCg1ucose), and maximum concentration of plasma glucose
reached after eating a meal (Cnax). Each of these measures
was compared to baseline and adjusted for baseline differences by comparing to placebo. Specific goals for significant
HbAlc reduction were set for each dose prior to the beginning of the trial. To reach desired goal for HbAlc compared
to baseline, a change -0.4, -0.5, -0.5 and -0.6 (p-value<0.05)
was required for 3.6, 7.3, 10.9 and 14.6 U* doses, respectively. When adjusted relative to placebo, HbAlc reduction
should reach -0.4, -0.67, -0.7 and -0.78 (p-value<0.04) for
above doses to be statistically significant. Secondary end-
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Table 1: Summary of HbA1c Results from data by Tack and colleagues 19
3.6 U* Tl

7.3 U*TI

10.9 U* Tl

14.6 U* Tl

Placebo

HbAlc change from baseline

-0.4±1.2

-0.5±1.2

-0.5±0.9

-0.6±1.1

0.2±0.9

p-value

0.05

0.004

0.002

0.001

0.098

HbAlc change from placebo
(corrected for baseline and basal insulin)

-0.4

-0.67

-0.7

-0.78

---

p-value

0.04

0.001

0.001

<0.001

---

points were to test safety by monitoring occurrence of adverse events.
Table 1 outlines HbAlc results related to Tl efficacy for the
trial, with statistically significant values in bold Based on
this data, all doses of Tl demonstrated a significant reduction
in HbAlc compared to placebo.19 Other measurements of Tl
efficacy found statistically significant results when comparing Tl to placebo at 10.9 and 14.6 U* doses for AUCg1ucose and
7.3, 10.9 and 14.6 U* doses for Cmax measurements. The data
shows with sufficient confidence that the reduction in HbAlc
is linked to increased dose of TI, and AUCg1ucose also decreases
at higher doses. No statistically significant differences were
found between Tl and placebo groups regarding adverse reactions, and Tl doses were well tolerated.
Tack and colleagues performed a strong clinical study by
standardizing titration of Tl doses, thoroughly documenting
criteria and data, and accounting for baseline differences
(although minimal) in their statistical analysis. The necessary
sample size (260) to achieve 80 percent power was calculated before the trial was performed, but only 227 patients
could be gathered, and only 205 completed the entire trial, so
there is a risk of type II error.19 The authors indicated the
forced titration design did not optimize treatment of patients, and the study was of short duration. Additionally, it
should be noted that this trial employed the MedTone® inhaler, not the DreamBoat® inhaler that MannKind is now
marketing with Tl.
Trial 2

Rosenstock and colleagues performed a randomized, multicenter, open-label, parallel-group study, funded by MannKind, assessing the efficacy and safety of prandial Tl
compared with twice daily biaspart insulin.20 The efficacy
endpoint was a change in HbAlc, and the main safety endpoints were hypoglycemia and cough. There were 677 patients included in the study (462 completed the study and
448 were analyzed in per-protocol population) aged 18 to 80
Fall 2014 Volume 6, Issue 1

years with type II OM and HbAlc greater than 7 percent and
less than 11 percent. Patients must have been nonsmokers
for at least six months before the study, have forced expiratory volume in one second (FEV1) of 70 percent, have total lung
capacity of 80 percent or higher, have a body mass index
(BM!) s40kg/m2, and need less than 1.4 JU insulin per kg.
Patients excluded from the study were those who had clinically significant diabetes complications, hepatic/renal disease, severe/several allergies, chronic pulmonary disease,
present drug or alcohol abuse, major psychiatric disorders,
myocardial infarction/stroke in the last three months or unstable diabetes (two or more episodes of severe hypoglycemia or any emergency room visit for diabetes in the last six
months). The data was collected over a period of 19 months.
Randomization was completed by an independent system
(ClinPhone, East Windsor, NJ, USA) to place the patients into
two groups in a 1:1 ratio, where one group would receive
prandial Tl powder plus bedtime insulin glargine by subcutaneous injection and the other would receive twice daily
premixed biaspart insulin by subcutaneous injection.20 No
blinding was used for this study because of the multicontinental study design and the drug administration times.
A 90 percent power was provided for the sample size of 677
patients for the comparison of HbAlc.20 The study used analysis of covariance (ANCOVA) to analyze the change in HbAlc,
FPG, PPG, weight and pulmonary function tests from baseline
after 52 weeks. The study utilized a paired t-test for
within-treatment comparisons, odds ratio for at least one
hypoglycemic event, Poisson regression model for rates of
hypoglycemic events, ANCOVA for between-treatment differences and logistic regression analysis to show the treatment
difference in responder rates. A short form-36 quality of life
(SF-36 QoL) and insulin treatment questionnaires were also
used to assess progress.
Data gathered from the trial with upper 95 percent confidence intervals (Cl) less than 0.4 showed Tl and insulin
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glargine was noninferior to biaspart insulin in HbAlc mean
changes from baseline.20 Mean FPG for TI plus insulin
glargine versus biaspart insulin at 52 weeks was 7.8mmol/L
(2.0mmol/L change from baseline; SD 0.3, 95% CJ -2.5 to
-1.5) and 8.7mmol/L (1.0mmol/L change from baseline; SD
0.2, 95% CI -1.5 to -0.5), respectively. The between-group
difference was -1.0mmol/L (SD 0.3, 95% CI -1.6 to -0.3,
p=0.0029). Postprandial blood glucose AUC for zero to 360
minutes was similar between both treatment groups:
59.8mmol/h per L for Tl and insulin glargine and 56.7mmol/
hr per L for biaspart insulin. However, the mean one hour
PPG levels were lower with Tl and insulin glargine versus
biaspart insulin (9.5mmol/L; SD 0.3 and ll.6mmolfL; SD 3.9,
p=0.0001). After two hours, glucose excursions were higher
with Tl and insulin glargine versus biaspart insulin, and glucose levels remained below baseline with biaspart insulin
after 200 minutes. Adverse events occurred in 272 patients
(84%) on Tl and insulin glargine and in 296 patients (89%)
on biaspart insulin. Hypoglycemia was the most common
adverse event occurring in 99 patients (31 %) on Tl and insulin glargine and 163 patients (49%) on biaspart insulin.
Cough was reported frequently with 103 patients (32%) on
Tl and insulin glargine and 14 patients (4%) on biaspart insulin. Most of the coughs from patients on Tl and insulin
glargine occurred within 10 minutes of inhalation. There
were no significant differences between the two groups with
pulmonary function.
Rosenstock and colleagues conclude that Tl plus insulin
glargine is an effective alternative to conventional subcutaneous insulin therapy in patients with type II OM, and it may
result in less weight gain and hypoglycemia.20

Trial 3

Raskin and colleagues performed a prospective, randomized,
open-label study to determine the pulmonary safety of Tl
versus usual diabetes medications in patients with DM.21 The
patients had either type I OM or type II OM and were stratified by OM type prior to randomization into prandial insulin
Tl (n=743) or usual antidiabetic (n=824) treatment groups.
The definition of "usual care" was determined by doctor discretion and could include any range of oral antidiabetic medications with or without insulin, and patients in the Tl group
also remained on other diabetes medications as needed. The
study also included a control group of 145 patients who did
not have OM and were not receiving treatment in order to
assess standard lung function. The primary objective of the
study was to evaluate change in pulmonary function of each
treatment group and determine if Tl pulmonary safety was
noninferior to usual care. To accomplish this, Raskin and colleagues measured lung function by the primary endpoint,
FEV1, and secondary endpoints forced vital capacity (FVC),
total Jung capacity (TLC) and lung diffusion capacity for carbon monoxide (DLco) for each patient at zero, three, six, 12,
18 and 24 months. Any adverse reactions were also assessed.
Baseline demographics and pulmonary function were determined to be similar between treatment groups of OM patients.
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Calculations for statistical analysis were based on the null
hypothesis that difference in FEV1 change was not less than
0.050 L/year ± 0.100 L in Tl groups compared to usual care
groups.21 To achieve 80 percent power and alpha of 0.05, it
was calculated a sample size of 50 patients for each treatment arm would be necessary. The number of patients enrolled well exceeded these requirements, so type II error in
statistical analysis is unlikely. Of 2,053 patients originally
enrolled in the study, 763 dropped out (mainly due to withdrawal of consent, not as a result of any major side effects),
leaving 1,699 patients who were included in the analysis.
Pulmonary function declined marginally in all groups compared to baseline, and overall pulmonary safety of Tl was
determined to be noninferior to usual care over the course of
two years.21 The primary endpoint met the noninferimity
goal with a mean change (Tl minus usual care) over two
years in FEV1=0.037 L (95% CI 0.014 to 0.060). Secondary
endpoint mean differences were FVC=0.034 L (95% Cl 0.008
to 0.06), TLC=0.005 L (95% CI -0.042 to 0.031), and
DLco=0.269mL/min/mm Hg (95% Cl -0.037 to 0.574). There
was a greater initial decline (zero to three months) in lung
function in the Tl group compared to the usual care group,
but when compared with data from three to 24 months,
there was no statistically significant difference between the
groups. Generally Tl was well tolerated with no safety concerns. The most common treatment-related adverse effect in
both groups was hypoglycemia. The second most common
adverse effect, a mild, nonproductive cough that occurred
within 10 minutes of inhalation, was more common in the Tl
group, but it did not affect overall lung function. It was reported by patients within the first month of therapy and declined over time. No Jung malignancy was reported in either
group. Raskin and colleagues concluded that any differences
in the change in Jung function between the Tl and usual care
groups was observed early and did not progress over two
years, so this is unlikely to have clinical significance. Overall,
the study was sufficient to indicate that Tl does not pose any
serious pulmonary safety concerns when used as intended.
Conclusion
Technosphere® insulin has great potential to meet the need
for medication that can imitate the fast-acting effects of endogenous insulin. Trials have proven it to be safe and efficacious as a rapid-acting insulin. The DreamBoat® inhaler is
small, portable and easy to use. Although effective as a rapidacting insulin, it is important to remember that Tl therapy
still requires administration of either injectable long-acting
insulin or other antidiabetic therapy to maintain basal insulin levels, and therefore it may not completely eliminate the
use of needles from a patient's therapy. The true benefit of Tl
remains to be seen. Largely its success will depend upon patient preference and whether or not the advantages it offers
can overcome the negative impression left by previous inhaled insulin.
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Assessment Questions
1. For what kinds of complications are OM patients at
higher risk than patients without OM?
A. Cardiovascular problems
B. Blindness
C. Kidney disease
D. All of the above

2.

What is the cause of type 1 DM?
A. Insulin resistance
B. The immune system destroys the beta cells in
the pancreas
C. Increased blood glucose levels during pregnancy
D. Obesity

3. According to the study done by Cramer and Pugh,
patients used what percent of their insulin prescriptions?
A. 50 percent
B. 67 percent
C. 77 percent
D. 80 percent
4. Which of the following were mentioned in this article as
alternative methods of insulin administration under
investigation?
A. Oral
B. Nasal
C. Transdermal
D. All of the above
5. What was the generic name of the inhaled insulin made
by Pfizer?
A. Insulin inhalation
B. Technosphere® insulin
C. Exubera®
D. Afrezza®
6. Which of the following accurately describes the
pharmacokinetics ofTechnosphere® insulin?
A. Achieves 37 percent bioavailability
B. Reaches peak insulin levels in 15 minutes
C. Lower postprandial blood glucose (PPG) levels
compared to subcutaneously injected insulin 30
to 120 minutes following a meal
D. Two of the above
E. All of the above
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7.

Which of the following accurately describes the
pharmacodynamics of Technosphere® insulin?
A. The neutral pH of the lungs slows absorption
B. Absorbed through the lung tissue into systemic
circulation
C. Smoking decreases its absorption
D. Two of the above
E. All of the above

8.

True or False: Technosphere® insulin's mechanism of
action is identical to prandial subcutaneously injected
insulin.
A. True
B. False

9.

All of the following are advantages of inhaled insulin
when compared to injectable insulin EXCEPT which one?
A Lower peak blood glucose
B. Lower PPG levels 30 to 120 minutes following a
meal
C. Lower AUCglucose
D. Lower FPG levels

10. How does the efficacy ofTechnosphere® insulin
compare to biaspart insulin?
A. Significantly better efficacy
B. Noninferior efficacy
C. Poor efficacy
D. Not enough information
11. What is the most common adverse reaction regarding
Technosphere® insulin?
A. Mild, nonproductive cough within 10 minutes of
inhalation
B. Decreased lung function
C. Lung cancer
D. None of the above
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Identify the different types of diabetes and each of their
pathophysiologies.

2

3

4

5

Name several investigational methods for insulin
administration.

2

3

4

5

Describe the pharmacokinetics and pharmacodynamics of
Technosphere® insulin.

2

3

4

5

2

3

4

5

The program met your educational needs.

2

3

4

5

Content of the program was interesting.

2

3

4

5

Material presented was relevant to my practice.

2

3

4

5

The program objectives were clear.
The program met the stated goals and objectives:

Explain the advantages and disadvantages of inhaled insulin
compared to injectable insulin.

1

Evaluate the efficacy and safety ofTechnosphere® insulin based on
data from clinical trials.

Comments/Suggestions for future programs:

Thank you!
Answers to Assess ment Questions-Please Circle Your Answer
1. A B

2. A B
3. A B

c
c
c

D

4.

A B

D

5.

A B

D

6.

A B

c
c
c

D

7. A B C D E

JO. A B

D

8. A B

11. A B

D E

9. A B

Any questions/comments regarding this continuing education program
can be directed to Lauren Hamman, Advanced Administrative Assistant
for the Office of Continuing Education (email: l-hammanl@onu.edu
phone 419-772-2280).
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D
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